Application of apocynin nitrone in preparing medicine for preventing and treating asthma

A technology of berberine and nitrone, which is applied in the field of ferberine nitrone in the field of preparing asthma prevention and treatment drugs, can solve the problem that the drug efficacy needs to be improved, and achieve the effects of enhancing the antioxidant effect and making up for the deficiency.

Inactive Publication Date: 2017-06-23
JINAN UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] To sum up, the existing asthma medicines still have deficiencies and need to be improved. Asthma takes chronic inflammation as one of the main treatment targets. Inflammation is closely related to oxidative stress. Many studie...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of apocynin nitrone in preparing medicine for preventing and treating asthma
  • Application of apocynin nitrone in preparing medicine for preventing and treating asthma
  • Application of apocynin nitrone in preparing medicine for preventing and treating asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Female BALB / c mice, weighing 20-25g, aged 6-8 weeks, were randomly divided into normal control group, OVA model group, berberine (Apo) group, berberine nitrone (AN-1) low and medium , high-dose group, positive drug dexamethasone (Dex) group, 11 in every group. Placed in an environment at 23±2°C with a lighting time of 12h / day, and the experiment began after the animals had adapted to the environment for one week. From the first day of the experiment, except for the normal control group, animals in each group were injected intraperitoneally with 200 μl of phosphate buffered saline (PBS) containing 10 μg of ovalbumin (OVA) and 1 mg of aluminum hydroxide, once every 7 days for 3 weeks. The normal control group was replaced by an equal volume of PBS. From the 21st day, except for the normal control group, the mice in each group were placed in a transparent airtight container, and the stimulation solution (PBS containing 20g / L OVA) was atomized for stimulation, once a day, ...

Embodiment 2

[0040] Female BALB / c mice, weighing 20-25g, aged 6-8 weeks, were randomly divided into normal control group, OVA model group, berberine (Apo) group, berberine nitrone (AN-1) low and medium , high-dose group, positive drug dexamethasone (Dex) group, 11 in every group. Placed in an environment at 23±2°C with a lighting time of 12h / day, and the experiment began after the animals had adapted to the environment for one week. From the first day of the experiment, except for the normal control group, animals in each group were injected intraperitoneally with 200 μl of phosphate buffered saline (PBS) containing 10 μg of ovalbumin (OVA) and 1 mg of aluminum hydroxide, once every 7 days for 3 weeks. The normal control group was replaced by an equal volume of PBS. From the 21st day, except for the normal control group, the mice in each group were placed in a transparent airtight container, and the stimulation solution (PBS containing 20g / L OVA) was atomized for stimulation, once a day, ...

Embodiment 3

[0043]Female BALB / c mice, weighing 20-25g, aged 6-8 weeks, were randomly divided into normal control group, OVA model group, berberine (Apo) group, berberine nitrone (AN-1) low and medium , high-dose group, positive drug isoproterenol group, 11 rats in each group. Placed in an environment at 23±2°C with a lighting time of 12h / day, and the experiment began after the animals had adapted to the environment for one week. From the first day of the experiment, except for the normal control group, animals in each group were intraperitoneally injected with 200 μl of phosphate buffered saline (PBS) containing 10 μg of ovalbumin (OVA) and 1 mg of aluminum hydroxide, once every 7 days for 3 weeks. The normal control group was replaced by an equal volume of PBS. From the 21st day, except for the normal control group, the mice in each group were placed in a transparent airtight container, and the stimulation solution (PBS containing 20g / LOVA) was atomized to challenge, once a day, 30min e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, and in particular discloses an application of apocynin nitrone in preparing a medicine for preventing and treating asthma. According to the invention, an OVA (ovalbumin) induced mouse asthma animal model, effects of the apocynin nitrone on resisting inflammation, resisting oxidation and relaxing trachea are researched by virtue of such research methods as an integral animal experiment, an isolated trachea experiment and the like. Based upon test results, the apocynin nitrone can obviously improve lung tissue inflammation of an asthma model mouse and subsequent lung tissue injury, inhibit the generation of inflammatory cell factors and reduce a lung wet/dry weight ratio and a lung penetration index. The apocynin nitrone can improve levels of superoxide dismutase and glutathione in lung tissue homogenate, reduce level of a lipid peroxidation product, namely malonaldehyde, and improve a lung oxidative stress state. The apocynin nitrone can reduce smooth muscle tension of the isolated trachea and improve tracheospasm. The apocynin nitrone provided by the invention, as an active ingredient, can be used for preparing a pharmaceutical composition for preventing and treating the asthma in the combination with a pharmaceutically acceptable carrier or excipient.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the use of berberine nitrone in the preparation of anti-asthma drugs. Background technique [0002] Asthma (Asthma) is a chronic airway inflammation that is affected by a variety of cells and cellular factors. It is a disease that is sensitized and stimulated by exogenous proteins to produce allergic inflammation. Common symptoms mainly include wheezing, shortness of breath, chest tightness, and coughing. The main clinical features include reversible airflow obstruction, pulmonary and bronchial hyperresponsiveness, and airway inflammation. The pathogenesis of asthma is relatively complex, and the response of helper T cells, the secretion of airway inflammatory cytokines, various triggering factors, genetic factors, and oxidative stress are all involved. Asthma symptoms generally attack and aggravate at night or in the early morning, and patients can develop symptoms...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/13A61P11/06
CPCA61K31/13
Inventor 蒋杰李沙丘智峰高瑞涛张志坚藕洋
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap